Back to results
US 2004/0082567 A1Published application
Compounds, compositions, and methods
AssigneesCytokinetics, Inc., SmithKline Beecham Corporation
InventorsAndrew McDonald, Pu-Ping Lu, Gustave Bergnes, David J. Morgans JR., Dashyant Dhanak, Steven David Knight
Life of this patent
Estimating the term…
Abstract
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
Claims48
A compound having the structure represented by Formula I:
- 35
- wherein:
- R1 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-;
- R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-;
- or R2 and R2′ taken together form an optionally substituted 3- to 7-membered ring;
- R12 is selected from the group consisting of optionally substituted imidazolyl-, optionally substituted imidazolinyl-, —NHR4;
- —N(R4)(COR3);
- —N(R4)(SO2R3a);
- and —N(R4)(CH2R3b);
- R3 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, R15O— and R17—NH—;
- R3a is chosen from optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, and R17—NH—;
- R3b is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted beteroaryl-, and optionally substituted heteroaralkyl-;
- R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted hetercyclyl-, and optionally substituted heteroaralkyl-;
- R5, R6, R7 and R8 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, optionally substituted aryl and optionally substituted heteroaryl;
- R15 is optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, or optionally substituted heteroaralkyl-;
- and
- R17 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
- a pharmaceutically acceptable salt of a compound of Formula I;
- a pharmaceutically acceptable solvate of a compound of Formula I;
- or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I.
17 more elements
Dependencies are inferred from the claim text.